Beijing Geekgene Technology Co., LTD
7
4
5
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid Tumors
Role: lead
A Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.
Role: lead
A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.
Role: lead
A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Solid Tumors
Role: collaborator
A Clinical Study of GK02 in Malignant Ascites
Role: lead
A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid Tumors
Role: collaborator
a Single-arm, Single-center, Open Clinical Study
Role: lead
All 7 trials loaded